• Eur J Ophthalmol · Jul 2011

    Case Reports

    Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab.

    • Andrew J Barkmeier, Huseyin Kadikoy, Eric R Holz, and Petros E Carvounis.
    • Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA.
    • Eur J Ophthalmol. 2011 Jul 1; 21 (4): 506-8.

    PurposeTo describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab.MethodsThe medical records of a patient with peripheral exudative chorioretinopathy were reviewed.ResultsMacular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course.ConclusionsBevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.